Phase III
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
FerGene, a gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, reported that its Phase III trial of nadofaragene firadenovec (rAd-IFN/Syn3) met its primary endpoint.
Biogen presented full data today on its Alzheimer’s drug aducanumab at the 12th Clinical Trials on Alzheimer’s Disease conference held in San Diego.
The company presented full trial data at the 12th Clinical Trials on Alzheimer’s Disease meeting in San Diego on Wednesday.
“This extraordinary pivotal data confirms voclosporin’s ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care,” said Neil Solomons, Aurinia’s chief medical officer.
The Phase III failure was certainly a setback for the company as it chased Janssen and its Esketamine-based treatment Spravato for MDD.
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
PRESS RELEASES